Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak in a Long-term Care Facility After Vaccination With BNT162b2

Emerging Evidence on Effectiveness of COVID-19 Vaccines Among Residents of Long-Term Care Facilities

“…Three studies from Germany, Northern Ireland, and the United States reported substantial outbreaks despite high first-dose vaccination rates of residents, with attack rates between 18% and 34% in affected facilities. 3,9 Potential for breakthrough infections in fully vaccinated residents (ie, infection occurred more than 2 weeks after administration of the second dose) was reported in studies from the United States and Northern Ireland. 4,10,11 Viral load in vaccinated, infected residents may be smaller compared with unvaccinated residents.…”

Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines

“…Similarly, a previous study in the UK with participants aged ≥70 years and vaccinated with a single dose of BNT162b2 or ChAdOx1 showed the association of vaccination with a significant reduction in symptomatic disease and severity COVID-19 [46]. Another study in an LTC facility reported that a single dose of BNT162b2 did not prevent severe or fatal COVID-19 in the elderly (median age = 88 years old) 3 weeks after the initial vaccination [47]. We report here the first fatal COVID-19 case in an 84 year old individual who received the complete series of CoronaVac vaccination.…”

Epidemiological and Genomic Analysis of a Large SARS-CoV-2 Outbreak in a Long-Term Care Facility in Catalonia, Spain

“…Furthermore, keeping the residential population safe from SARS-CoV-2 infection indirectly preserves the general well-being (avoidance of lockdowns and isolations) and reduces its burden on the health system. The precise dynamics of the introduction, expansion, and severity of the infection in residential premises are still not well understood, and reports of outbreaks that occurred at these facilities are very scarce, with half of them providing no or very limited SARS-CoV-2 genomic information ( 10 to 15 ). Therefore, an in-depth analysis of a specific outbreak using classical and genomic epidemiology approaches may help to answer these questions and guide the implementation of more efficient measures to prevent and mitigate SARS-CoV-2 outbreaks in LTCFs.…”